http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kyu-shik Jeong,정원일,Jae-yong Chung,Mi-young An,Chae-yong Jung,Gyoung-jae Lee,Jong-soo Kang,Byeong-cheol Kang,Young-heun Jee,Bruce H Williams,Young-oh Kwon,Da-hee Jeong 대한수의학회 2003 Journal of Veterinary Science Vol.4 No.2
Cirrhosis Occurring in a Young Woodchuck (Marmota monax) Due to Vertical Transmission of Woodchuck Hepatitis Virus (WHV)Da-hee Jeong, Won-il Jeong, Jae-yong Chung, Mi-young An, Chae-yong Jung, Gyoung-jae Lee1, Jong-soo Kang1, Byeong-cheol Kang2, Young-heun Jee3, Bruce H Williams4, Young-oh Kwon5 and Kyu-shik Jeong*College of Veterinary Medicine, Kyungpook National University, Daegu 702-701, Korea1Shinwon Scientific Co., LTD, Research Institute, Suwon, Korea2Clinical Research Institute, Seoul National University, Seoul 110-744, Korea3College of Veterinary Medicine, Jeju National University, Jeju 690-756, Korea
William Henry Eskew,Jesus Beltran-Perez,Bruce Bordlee 소화기인터벤션의학회 2024 International journal of gastrointestinal interven Vol.13 No.1
Gastrointestinal (GI) bleeding is a serious complication with a high mortality rate (45%–55%) that can result from a variety of conditions, including portal hypertension, diverticulosis, or splenic vein thrombosis. There are a variety of established treatment strategies for GI bleeds, and there are different indications and contraindications for each. In this case, colonoscopy did not identify any active source of bleeding. Furthermore, because this GI hemorrhage did not involve any shunts, balloon-occluded retrograde transvenous obliteration was not performed. Additionally, a transjugular intrahepatic portosystemic shunt was ruled out due to the poor primary shunt patency rate. Here, we report the treatment of a GI bleed with N-butyl- 2-cyanoacrylate (n-BCA) liquid embolization with no complications. This case demonstrates the potential of using n-BCA to treat small bowel varices.
OH, WILLIAM K.,McDERMOTT, DAVID,PORTA, CAMILLO,LEVY, ANTONIN,ELAIDI, REZA,SCOTTE, FLORIAN,HAWKINS, ROBERT,CASTELLANO, DANIEL,BELLMUNT, JOAQUIM,RHA, SUN YOUNG,SUN, JONG-MU,NATHAN, PAUL,FEINBERG, BRUCE D.A. Spandidos 2014 International journal of oncology Vol.44 No.1
<P>The aim of this study was to assess the treatment patterns and safety of sunitinib, sorafenib and bevacizumab in real-world clinical settings in US, Europe and Asia. Medical records were abstracted at 18 community oncology clinics in the US and at 21 tertiary oncology centers in US, Europe and Asia for 883 patients ≥18 years who had histologically/cytologically confirmed diagnosis of advanced RCC and received sunitinib (n=631), sorafenib (n=207) or bevacizumab (n=45) as first-line treatment. No prior treatment was permitted. Data were collected on all adverse events (AEs) and treatment modifications, including discontinuation, interruption and dose reduction. Treatment duration was estimated using Kaplan-Meier analysis. Demographics were similar across treatment groups and regions. Median treatment duration ranged from 6.1 to 10.7 months, 5.1 to 8.5 months and 7.5 to 9.8 months for sunitinib, sorafenib and bevacizumab patients, respectively. Grade 3/4 AEs were experienced by 26.0, 28.0 and 15.6% of sunitinib, sorafenib and bevacizumab patients, respectively. Treatment discontinuations occurred in 62.4 (Asia) to 63.1% (US) sunitinib, 68.8 (Asia) to 90.0% (Europe) sorafenib, and 66.7 (Asia) to 81.8% (US) bevacizumab patients. Globally, treatment modifications due to AEs occurred in 55.1, 54.2 and 50.0% sunitinib, sorafenib and bevacizumab patients, respectively. This study in a large, global cohort of advanced RCC patients found that angiogenesis inhibitors are associated with high rates of AEs and treatment modifications. Findings suggest an unmet need for more tolerable agents for RCC treatment.</P>